Accepted for Publication: December 14, 2021.
Published: February 21, 2022. doi:10.1001/jamanetworkopen.2022.0130
Correction: This article was corrected on April 8, 2022, to fix an error in Supplement 2.
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Várnai C et al. JAMA Network Open.
Corresponding Author: Gary Middleton, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, United Kingdom (email@example.com).
Author Contributions: Profs Middleton and Cazier had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Várnai, Palles, Arnold, and Curley contributed equally. Profs Middleton and Cazier contributed equally.
Concept and design: Várnai, Palles, Arnold, Purshouse, Booth, Campton, Hughes, A. Lee, Olsson-Brown, Sharma-Oates, L. Lee, Kerr, Middleton, Cazier.
Acquisition, analysis, or interpretation of data: Várnai, Palles, Arnold, Curley, Purshouse, Cheng, Booth, Campton, Collins, Hughes, Kulasekararaj, A. Lee, Olsson-Brown, Sharma-Oates, Van Hemelrijck, L. Lee, Kerr, Cazier.
Drafting of the manuscript: Várnai, Palles, Arnold, Curley, Purshouse, Cheng, Booth, Hughes, Kulasekararaj, A. Lee, Olsson-Brown, Sharma-Oates, L. Lee, Kerr, Middleton, Cazier.
Critical revision of the manuscript for important intellectual content: Várnai, Palles, Arnold, Curley, Booth, Campton, Collins, Hughes, A. Lee, Olsson-Brown, Van Hemelrijck, Kerr, Cazier.
Statistical analysis: Várnai, Palles, Curley, Sharma-Oates, Cazier.
Obtained funding: Palles, Curley, Booth, L. Lee, Cazier.
Administrative, technical, or material support: Curley, Purshouse, Cheng, Booth, Campton, A. Lee, Van Hemelrijck, L. Lee, Cazier.
Supervision: Palles, Booth, Collins, Olsson-Brown, Kerr, Middleton, Cazier.
Conflict of Interest Disclosures: Dr Palles reported receiving grants from Blood Cancer UK and Bowel Cancer UK during the conduct of the study. Dr Arnold reported receiving grants from Blood Cancer UK during the conduct of the study. Dr Curley reported receiving grants from Blood Cancer UK during the conduct of the study. Dr Purshouse reported receiving a fellowship from the Wellcome Trust during the conduct of the study. Dr Hughes reported received research funding from Nanomab Technology, personal fees from Pfizer, and speakers’ fees from Novartis outside the submitted work. Dr Olsson-Brown reported receiving grant support from Roche, Bristol Myers Squibb, Eli Lilly and Co, Novartis, and UCB Pharma and receiving personal fees from Roche, Merck Sharpe and Dohme, Eisai, and Bristol Myers Squibb outside the submitted work. Prof Middleton reported receiving personal fees from Bristol Myers Squibb, Servier, Roche, Merck Sharpe and Dohme, AstraZeneca, Pfizer, and D2G outside the submitted work. Prof Cazier reported grants from Blood Cancer UK during the conduct of the study. No other disclosures were reported.
Funding/Support: The work was supported by University of Birmingham, University of Oxford, Blood Cancer UK (grant No. 20011), Cancer Research UK (grant No. C17422/A25154), and Bowel Cancer UK (grant No. 18PG0010).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: A complete list of the members of the UKCCMP Team appears in Supplement 2.
Additional Contributions: We thank the patients and their families affected by COVID-19, oncologists, acute physicians, and health care staff working tirelessly on the frontlines of the COVID-19 pandemic. We thank all members of the UK Coronavirus Cancer Monitoring Project reporting network and emergency response reporting individuals for their hard work in contributing data at a challenging time.
Additional Information: Full anonymized data and analytical methods from the UKCCMP will be made available with publication upon request to the UKCCMP (https://ukcoronaviruscancermonitoring.com/) and subject to approval by the UKCCMP Executive Committee with a signed data access agreement for clinical and research applications.
LY , Cazier
J-B , Angelis
et al; UK Coronavirus Monitoring Project Team. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet
. 2020;395(10241):1919-1926. doi:10.1016/S0140-6736(20)31173-9PubMedGoogle ScholarCrossref
LYW , Cazier
J-B , Starkey
et al; UK Coronavirus Cancer Monitoring Project Team. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol
. 2020;21(10):1309-1316. doi:10.1016/S1470-2045(20)30442-3PubMedGoogle ScholarCrossref
PA , Taylor
R , Thielke
R , Payne
J , Gonzalez
N , Conde
JG . Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform
. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010PubMedGoogle ScholarCrossref
PA , Taylor
R , Minor
et al; REDCap Consortium. The REDCap consortium: building an international community of software platform partners. J Biomed Inform
. 2019;95:103208. doi:10.1016/j.jbi.2019.103208PubMedGoogle Scholar
E , Altman
DG , Egger
M , Pocock
SJ , Gøtzsche
PC , Vandenbroucke
JP ; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg
. 2014;12(12):1495-1499. doi:10.1016/j.ijsu.2014.07.013PubMedGoogle ScholarCrossref
MC , Whisenant
JG , Huang
et al; TERAVOLT investigators. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol
. 2020;21(7):914-922. doi:10.1016/S1470-2045(20)30314-4PubMedGoogle ScholarCrossref
J , Torri
V , Whisenant
et al. LBA75 defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic Cancers International COVID 19 Collaboration). Ann Oncol
. 2020;31: S1204–S1205. doi:10.1016/j.annonc.2020.08.2316Google ScholarCrossref
P , Khaki
AR , Wise-Draper
et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol
. 2021;32(6):787-800. doi:10.1016/j.annonc.2021.02.024PubMedGoogle ScholarCrossref
AJ , Nightingale
P , Naidu
B , Drayson
MT , Middleton
GW , Richter
A . Characterising the impact of pneumonia on outcome in non-small cell lung cancer: identifying preventative strategies. J Thorac Dis
. 2020;12(5):2236-2246. doi:10.21037/jtd.2020.04.49PubMedGoogle ScholarCrossref
CH , Curtis
JL . Implications of the GOLD COPD classification and guidelines. Fed Pract
. 2015;32(suppl 10):14S-18S.PubMedGoogle Scholar